Annie Lau-Kilby

Global Medical Director for Immunology pipeline

(Dazodalibep and AMG-329 - Sjogren's Disease; Daxdilimab - SLE, LN, CLE, myositis, alopecia)

• Owns global medical strategy across early- and late-stage assets, alinging evidence generation, external engagement and lifecycle planning
• Partner on cross-functional product strategy with R&D, Commercial, HEOR, and Access to inform differentiation and launch readiness
• Lead evidence generation strategy including RWE and observational studies to support access and scientific value story
• Partner with global and regional field medical teams to accelerate clinical trial enrollment and optimize investigator and site engagement
• Lead and mentor a global matrix medical team and serving as a core member of the rare disease medical leadership team
• Shape and execute external engagement strategy including global congresses, symposiums, publications and advisory boards
• Develop disease state education strategy using AI-enabled and integrated omnichannel approaches
• Own medical budget and resource allocation, balancing strategic priorities in dynamic pipeline environment

• Recipient, 2021 Horizon R&D Scientific Leadership Award, recognizing excellence in translational strategy and cross-functional scientific leadership.
• Serve as Translational Medicine (TM) Lead for multiple Phase 1–2 clinical assets with distinct mechanisms of action, driving end-to-end biomarker and translational strategy from pre-IND through early clinical development.
• Design, develop, validate, and execute clinical biomarker strategies, leveraging state-of-the-art technologies and platforms to inform dose selection, patient stratification, and proof-of-mechanism.
• Partner cross-functionally with Clinical Development, Clinical Operations, Medical Affairs, and Patient Advocacy to align translational objectives with clinical study design and execution.
• Lead scientific collaborations with global KOLs, generating mechanistic and translational rationale to support follow-on indications, disease selection, and lifecycle strategy.
• Chair and present at scientific advisory boards, translating expert insights into actionable recommendations for clinical study design and biomarker development.
• Build, lead, and scale a TM Operations team, overseeing biospecimen logistics, assay development, and high-quality data generation across all clinical programs.
• Evaluate and provide scientific due diligence for external R&D opportunities, supporting portfolio expansion and partnering decisions.

• Lead preclinical research teams to generate translational data supporting clinical programs, disease selection, and IND-enabling strategies.
• Serve as Product Development Team Lead (PDTL) for early-stage programs, defining product strategy and integrated development plans aligned with disease biology and value optimization.
• Author, review, and support IND submissions, contributing nonclinical and translational sections and ensuring regulatory readiness.
• Identify, select, and manage CROs and academic collaborators to execute preclinical studies supporting product development and clinical trial design.
• Partner closely with Translational Science on nonclinical and clinical studies, including biomarker development and translational alignment.
• Identify and evaluate novel therapeutic targets, leading target validation strategies through functional assay design and preclinical efficacy studies.
• Manage, mentor, and develop direct reports, fostering scientific rigor, accountability, and career growth within the research team.

Defining the role of innate responses and dendritic cell subsets in driving neonatal T cell responses during RSV infection

NIDDK (2008-2011): Interleukin-2 controls the development and function of Dendritic cells in Type 1 diabetes.

Vaccine Research Center (VRC), NIAID (2011-2014): The development of Adenovector-based Vaccines for acute and durable protection against Ebola virus infection